BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Feb 21, 2024
Distillery Therapeutics

Serotonin receptor antagonist for MASH

BioCentury | Feb 23, 2021
Product Development

Meniere disease pipeline: Data Byte

Otonomy’s negative Phase III readout calls into question the utility of targeting the glucocorticoid receptor to treat Meniere disease.  There are no approved drugs to treat the disorder,
BioCentury | Dec 1, 2017
Clinical News

Auris misses in Phase III hearing loss trial

BioCentury | Apr 20, 2017
Clinical News

TNX-102 SL: Ph III HONOR started

BioCentury | Mar 10, 2017
Clinical News

Zerviate regulatory update

Items per page:
1 - 10 of 127